GO
Loading...

Salix Pharmaceuticals Ltd

More

  • *AbbVie to pay $261.25 per share in cash and stock. The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago- based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical...

  • Salix reports 4Q loss Monday, 2 Mar 2015 | 5:14 PM ET

    RALEIGH, N.C. _ Salix Pharmaceuticals Ltd. on Monday reported a fourth-quarter loss of $287.6 million, after reporting a profit in the same period a year earlier. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of 15 cents per share. Analysts expected $233.9 million, according to Zacks.

  • Cramer Remix: Where's the Nasdaq bubble? Monday, 23 Feb 2015 | 7:02 PM ET
    Jim Cramer on the set of Mad Money

    As Apple hits new highs, "Mad Money" host Jim Cramer is betting on it to lift the Nasdaq.

  • Cramer: Fastest growing major pharma headed higher Monday, 23 Feb 2015 | 6:45 PM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    This major pharmaceutical company just announced a huge deal. Jim Cramer thinks this is just the beginning.

  • Nasdaq stocks posting largest volume increases Monday, 23 Feb 2015 | 6:04 PM ET

    Axion Power International Inc.: Approximately 2,343,400 shares changed hands, a 2,862.8 percent increase over its 65- day average volume. The shares fell$. 14 or 30.4 percent to$. 32. The shares fell$. 17 or 76.8 percent to$. 05.

  • NEW YORK, Feb 23- The Nasdaq ended higher on Monday for a ninth straight day following gains in Apple, while the Dow and S&P 500 eased off recent record highs as lower oil prices dragged down energy shares. Nasdaq's winning run was its longest since September 2010, putting the index closer to its 5,132.52 all-time intraday high, reached in March 2000 just before the...

  • Four trades to go before the closing bell Monday, 23 Feb 2015 | 1:42 PM ET

    The "Halftime Report" traders give their final trades of the show.

  • NEW YORK, Feb 23- U.S. stocks were down slightly in midday trading Monday as lower oil prices dragged down energy shares, pulling the Dow and S&P 500 off recent record levels. Oil prices fell, with WTI crude off $1.30 at $49.50 a barrel on oversupply concerns and a stronger dollar, pushing the S&P energy index down 0.6 percent. Investors were also reluctant to make big...

  • Most active Nasdaq-traded stocks Monday, 23 Feb 2015 | 1:20 PM ET

    American Realty Capital Properties Inc. rose 3.3 percent to $9.75 with 20,744,800 shares traded. Apple Inc. rose 2.7 percent to $133.00 with 66,495,800 shares traded. Biocept Inc. rose 51.7 percent to $2.20 with 20,900,800 shares traded.

  • Feb 23- Rare disease drugmaker PTC Therapeutics Inc is exploring a potential sale amid takeover interest from several pharmaceutical companies, including Shire Plc and BioMarin Pharmaceutical Inc, according to people familiar with the matter. The stock of PTC Therapeutics, which has a market valuation of roughly $2 billion, rose as much as 25 percent to...

  • NEW YORK, Feb 23- U.S. stocks edged lower in morning trading Monday amid weakness in oil prices, after a conditional agreement by euro zone finance ministers to extend Greece's bailout sent the Dow and S&P to record levels last week. Investors were also reluctant to make big bets before Federal Reserve Chair Janet Yellen's semiannual testimony on the economy and...

  • Greece will present its economic reform plans on Monday to seal the euro zone financial lifeline, but the government drew criticism from a veteran leftist and ruling party member that the deal let voters down. The deal is conditional on Greece's European and IMF creditors accepting a list of reforms drawn up by Greece. "In spite of Germany taking a hard line, the...

  • Investors were looking ahead to the start of a two-day round of Congressional testimony by Federal Reserve Chair Janet Yellen. "The markets are in a holding pattern," said Erik Davidson, chief investment officer of Wells Fargo Private Bank. "We'll have some very interesting information coming up from Janet Yellen tomorrow and Wednesday, so the markets are...

  • NEW YORK, Feb 23- U.S. stocks were poised to open modestly lower on Monday, after the Dow and S&P closed at records on the heels of an agreement by euro zone finance ministers to extend Greece's bailout by four months provided it draws up a list of reforms. Greece will present its economic reform plans on Monday to seal the euro zone financial lifeline, but the...

  • NEW YORK, Feb 23- U.S. stock index futures dipped on Monday, after the Dow and S&P closed at records on the heels of an agreement by euro zone finance ministers to extend Greece's bailout by four months provided it draws up a list of reforms. *Greece will present its economic reform plans on Monday to seal the euro zone financial lifeline, but the government drew...

  • Early movers: GS, AAPL, DG, DISH, HMC & more Monday, 23 Feb 2015 | 7:41 AM ET
    Traders work on the floor of the New York Stock Exchange, Feb. 20, 2015.

    Some of the names on the move ahead of the open.

  • Canadian drugmaker Valeant Pharmaceuticals International Inc. has agreed to buy Salix Pharmaceuticals Ltd. for about $10 billion in cash. The deal is a win for Valeant, which made several offers to buy Allergan last year, but was repeatedly rebuffed by the Botox-maker. Allergan agreed to be acquired by Ireland- based Actavis in November.

  • NEW YORK, Feb 22- Canada's Valeant Pharmaceuticals International Inc. agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd. in an all-cash deal valued at about $10.1 billion, the two companies said on Sunday. The deal is the largest ever for Laval, Quebec- based Valeant, which lost a take-over contest for Allergan Inc last year.

  • Valeant to acquire Salix in $14.5 bln deal Sunday, 22 Feb 2015 | 4:46 PM ET

    NEW YORK, Feb 22- Valeant Pharmaceuticals International Inc. agreed to acquire Salix Pharmaceuticals Ltd. for $158.00 per share, or a total enterprise value of $14.5 billion, the two companies said on Sunday. The transaction, an all-cash tender offer for all the outstanding shares of Salix, was approved by the boards of directors of both companies, the companies...

  • Drugmaker Valeant to buy Salix for $14.5 billion Sunday, 22 Feb 2015 | 4:07 PM ET

    Salix, a maker of gastrointestinal drugs that has been courted by at least four potential suitors over the last year, has finally found a buyer.